M. Spada, S. Pagliardini u. a.: High incidence of later-onset fabry disease revealed by newborn screening. In: American journal of human genetics. Band 79, Nummer 1, Juli 2006, S. 31–40, doi:10.1086/504601. PMID 16773563. PMC 1474133 (freier Volltext).
W. L. Hwu, Y. H. Chien u. a.: Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). In: Human mutation. Band 30, Nummer 10, Oktober 2009, S. 1397–1405, doi:10.1002/humu.21074. PMID 19621417. PMC 2769558 (freier Volltext).
H. Y. Lin, K. W. Chong u. a.: High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. In: Circulation. Cardiovascular genetics. Band 2, Nummer 5, Oktober 2009, S. 450–456, doi:10.1161/CIRCGENETICS.109.862920. PMID 20031620.
P. Gaspar, J. Herrera u. a.: Frequency of Fabry disease in male and female haemodialysis patients in Spain. In: BMC medical genetics. Band 11, 2010, S. 19, doi:10.1186/1471-2350-11-19. PMID 20122163. PMC 2837018 (freier Volltext).
A. P. Burlina, K. B. Sims u. a.: Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. In: BMC neurology. Band 11, 2011, S. 61, doi:10.1186/1471-2377-11-61. PMID 21619592. PMC 3126707 (freier Volltext).
L. L. Pinto, T. A. Vieira u. a.: Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 14, doi:10.1186/1750-1172-5-14. PMID 20509947. PMC 2889886 (freier Volltext). (Review im Open Access)
D. P. Germain, K. Benistan, L. Angelova: X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. In: La Revue de médecine interne. Band 31, Suppl 2, Dezember 2010, S. S209–S213, doi:10.1016/S0248-8663(10)70013-8. PMID 21211665.
W. B. Dobyns, A. Filauro u. a.: Inheritance of most X-linked traits is not dominant or recessive, just X-linked. In: American journal of medical genetics. Part A. Band 129A, Nummer 2, August 2004, S. 136–143, doi:10.1002/ajmg.a.30123. PMID 15316978.
W. B. Dobyns: The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. In: Acta paediatrica. Band 95, Nummer 451, April 2006, S. 11–15, doi:10.1111/j.1651-2227.2006.tb02383.x. PMID 16720459.
M. Kobayashi, T. Ohashi u. a.: Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. In: Journal of inherited metabolic disease. [elektronische Veröffentlichung vor dem Druck] Januar 2008, doi:10.1007/s10545-007-0740-6. PMID 18202903.
E. M. Maier, S. Osterrieder u. a.: Disease manifestations and X inactivation in heterozygous females with Fabry disease. In: Acta paediatrica. Band 95, Nummer 451, April 2006, S. 30–38, doi:10.1111/j.1651-2227.2006.tb02386.x. PMID 16720462.
M. D. Sanchez-Niño, A. B. Sanz u. a.: Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. In: Nephrology, dialysis, transplantation. Band 26, Nummer 6, Juni 2011, S. 1797–1802, doi:10.1093/ndt/gfq306. PMID 20504837.
A. C. Vedder, G. E. Linthorst u. a.: Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. In: PloS one. Band 2, Nummer 7, 2007, S. e598, doi:10.1371/journal.pone.0000598. PMID 17622343. PMC 1913555 (freier Volltext). (Open Access)
P. B. Deegan, A. F. Baehner u. a.: Natural history of Fabry disease in females in the Fabry Outcome Survey. In: Journal of medical genetics. Band 43, Nummer 4, April 2006, S. 347–352, doi:10.1136/jmg.2005.036327. PMID 16227523. PMC 2563231 (freier Volltext).
A. C. Vedder, G. E. Linthorst u. a.: The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. In: Journal of inherited metabolic disease. Band 30, Nummer 1, Februar 2007, S. 68–78, doi:10.1007/s10545-006-0484-8. PMID 17206462.
A. C. Vedder, A. Strijland u. a.: Manifestations of Fabry disease in placental tissue. In: Journal of inherited metabolic disease. Band 29, Nummer 1, Februar 2006, S. 106–111, doi:10.1007/s10545-006-0196-0. PMID 16601876.
J. M. Aerts, J. E. Groener u. a.: Elevated globotriaosylsphingosine is a hallmark of Fabry disease. In: PNAS. Band 105, Nummer 8, Februar 2008, S. 2812–2817, doi:10.1073/pnas.0712309105. PMID 18287059. PMC 2268542 (freier Volltext).
D. A. Laney, D. J. Gruskin u. a.: Social-adaptive and psychological functioning of patients affected by Fabry disease. In: Journal of inherited metabolic disease. Januar 2010, doi:10.1007/s10545-009-9025-6. PMID 20087663.
A. L. Cole, P. J. Lee u. a.: Depression in adults with Fabry disease: a common and under-diagnosed problem. In: Journal of inherited metabolic disease. Band 30, Nummer 6, November 2007, S. 943–951, doi:10.1007/s10545-007-0708-6. PMID 17994284.
P. Segal, Y. Kohn u. a.: Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study. In: Journal of inherited metabolic disease. Band 33, Nummer 4, August 2010, S. 429–436, doi:10.1007/s10545-010-9133-3. PMID 20549363.
T. W. Crosbie, W. Packman, S. Packman: Psychological aspects of patients with Fabry disease. In: Journal of inherited metabolic disease. Band 32, Nummer 6, Dezember 2009, S. 745–753, doi:10.1007/s10545-009-1254-1. PMID 19924564.
B. Hoffmann, M. Beck u. a.: Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. In: The Clinical journal of pain. Band 23, Nummer 6, Jul-Aug 2007, S. 535–542, doi:10.1097/AJP.0b013e318074c986. PMID 17575495.
R. J. Hopkin, J. Bissler u. a.: Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. In: Pediatric research. Band 64, Nummer 5, November 2008, S. 550–555, doi:10.1203/PDR.0b013e318183f132. PMID 18596579.
B. Hoffmann, M. Schwarz u. a.: Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. In: Clinical gastroenterology and hepatology. Band 5, Nummer 12, Dezember 2007, S. 1447–1453, doi:10.1016/j.cgh.2007.08.012. PMID 17919989.
C. H. Orteu, T. Jansen u. a.: Fabry disease and the skin: data from FOS, the Fabry outcome survey. In: The British journal of dermatology. Band 157, Nummer 2, August 2007, S. 331–337, doi:10.1111/j.1365-2133.2007.08002.x. PMID 17573884.
S. N. Gupta, M. Ries u. a.: Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study. In: BMC neurology. Band 8, 2008, S. 41, doi:10.1186/1471-2377-8-41. PMID 18990229. PMC 2585087 (freier Volltext). (Open Access)
C. M. Eng, D. P. Germain u. a.: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. In: Genetics in medicine. Band 8, Nummer 9, September 2006, S. 539–548, doi:10.1097/01.gim.0000237866.70357.c6. PMID 16980809. (Review).
T. T. Nguyen, T. Gin u. a.: Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. In: Clinical & experimental ophthalmology. Band 33, Nummer 2, April 2005, S. 164–168, doi:10.1111/j.1442-9071.2005.00990.x. PMID 15807825.
A. Sodi, A. S. Ioannidis u. a.: Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. In: The British journal of ophthalmology. Band 91, Nummer 2, Februar 2007, S. 210–214, doi:10.1136/bjo.2006.100602. PMID 16973664. PMC 1857640 (freier Volltext).
K. Falke, A. Büttner u. a.: The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. In: Graefe’s archive for clinical and experimental ophthalmology. Band 247, Nummer 4, April 2009, S. 523–534, doi:10.1007/s00417-008-0962-9. PMID 18931853.
A. B. Fogo, L. Bostad u. a.: Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). In: Nephrology, dialysis, transplantation. Band 25, Nummer 7, Juli 2010, S. 2168–2177, doi:10.1093/ndt/gfp528. PMID 19833663. PMC 2902894 (freier Volltext).
T. Thomaidis, M. Relle u. a.: Wirkung der Enzymersatztherapie (ERT) auf die Nierenfunktion von Patienten mit Morbus Fabry. In: Medizinische Klinik. Band 104, Nummer 9, September 2009, S. 699–703, doi:10.1007/s00063-009-1152-1. PMID 19779674. (Review).
R. Schiffmann, D. G. Warnock u. a.: Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. In: Nephrology, dialysis, transplantation. Band 24, Nummer 7, Juli 2009, S. 2102–2111, doi:10.1093/ndt/gfp031. PMID 19218538. PMC 2698092 (freier Volltext).
J. S. Shah, D. A. Hughes u. a.: Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. In: The American journal of cardiology. Band 96, Nummer 6, September 2005, S. 842–846, doi:10.1016/j.amjcard.2005.05.033. PMID 16169374.
P. M. Elliott, H. Kindler u. a.: Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. In: Heart. Band 92, Nummer 3, März 2006, S. 357–360, doi:10.1136/hrt.2004.054015. PMID 16085718. PMC 1860797 (freier Volltext).
F. Weidemann, F. Breunig u. a.: The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. In: European heart journal. Band 26, Nummer 12, Juni 2005, S. 1221–1227, doi:10.1093/eurheartj/ehi143. PMID 15728649.
C. Kampmann, A. Linhart u. a.: Onset and progression of the Anderson-Fabry disease related cardiomyopathy. In: International journal of cardiology. Band 130, Nummer 3, November 2008, S. 367–373, doi:10.1016/j.ijcard.2008.03.007. PMID 18572264.
T. Takenaka, H. Teraguchi u. a.: Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. In: Journal of cardiology. Band 51, Nummer 1, Februar 2008, S. 50–59, doi:10.1016/j.jjcc.2007.12.001. PMID 18522775.
M. Pieroni, C. Chimenti u. a.: Early detection of Fabry cardiomyopathy by tissue Doppler imaging. In: Circulation. Band 107, Nummer 15, April 2003, S. 1978–1984, doi:10.1161/01.CIR.0000061952.27445.A0. PMID 12668521.
F. Weidemann, F. Breunig u. a.: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. In: Circulation. Band 108, Nummer 11, September 2003, S. 1299–1301, doi:10.1161/01.CIR.0000091253.71282.04. PMID 12952834.
T. Palecek, G. Dostalova u. a.: Right ventricular involvement in Fabry disease. In: Journal of the American Society of Echocardiography. Band 21, Nummer 11, November 2008, S. 1265–1268, doi:10.1016/j.echo.2008.09.002. PMID 18835697.
M. Niemann, F. Breunig u. a.: The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. In: Heart. Band 96, Nummer 23, Dezember 2010, S. 1915–1919, doi:10.1136/hrt.2010.204586. PMID 20965976.
A. Fellgiebel, M. J. Müller, L. Ginsberg: CNS manifestations of Fabry’s disease. In: Lancet neurology. Band 5, Nummer 9, September 2006, S. 791–795, doi:10.1016/S1474-4422(06)70548-8. PMID 16914407.
P. Mitsias, S. R. Levine: Cerebrovascular complications of Fabry’s disease. In: Annals of neurology. Band 40, Nummer 1, Juli 1996, S. 8–17, doi:10.1002/ana.410400105. PMID 8687196.
R. Okeda, M. Nisihara: An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. In: Neuropathology. Band 28, Nummer 5, Oktober 2008, S. 532–540, doi:10.1111/j.1440-1789.2008.00883.x. PMID 18410273.
A. Fellgiebel, I. Keller u. a.: Diagnostic utility of different MRI and MR angiography measures in Fabry disease. In: Neurology. Band 72, Nummer 1, Januar 2009, S. 63–68, doi:10.1212/01.wnl.0000338566.54190.8a. PMID 19122032.
C. R. Kaneski, D. F. Moore u. a.: Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. In: Neurology. Band 67, Nummer 11, Dezember 2006, S. 2045–2047, doi:10.1212/01.wnl.0000247278.88077.09. PMID 17159117. PMC 1950664 (freier Volltext).
A. Palla, S. Hegemann u. a.: Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. In: Journal of neurology. Band 254, Nummer 10, Oktober 2007, S. 1433–1442, doi:10.1007/s00415-007-0575-y. PMID 17934877.
Y. Sakurai, H. Kojima u. a.: The hearing status in 12 female and 15 male Japanese Fabry patients. In: Auris, nasus, larynx. Band 36, Nummer 6, Dezember 2009, S. 627–632, doi:10.1016/j.anl.2009.01.001. PMID 19261412.
S. Magage, J. C. Lubanda u. a.: Atteinte respiratoire de la maladie de Fabry. In: Médecine sciences. Band 21, Nummer 11 Suppl, Dezember 2005, S. 37–39, doi:10.1051/medsci/20052111s37. PMID 16324666.
S. Magage, J. C. Lubanda u. a.: Natural history of the respiratory involvement in Anderson-Fabry disease. In: Journal of inherited metabolic disease. Band 30, Nummer 5, Oktober 2007, S. 790–799, doi:10.1007/s10545-007-0616-9. PMID 17619837.
D. P. Germain, K. Benistan u. a.: Atteinte osseuse de la maladie de Fabry. In: Médecine sciences. Band 21, Nummer 11 Suppl, Dezember 2005, S. 43–44, doi:10.1051/medsci/20052111s43. PMID 16324668.
D. P. Germain, K. Benistan u. a.: Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. In: Clinical genetics. Band 68, Nummer 1, Juli 2005, S. 93–95, doi:10.1111/j.1399-0004.2005.00457.x. PMID 15952993.
H. Mersebach, J. O. Johansson u. a.: Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. In: Genetics in medicine. Band 9, Nummer 12, Dezember 2007, S. 812–818, doi:10.1097/GIM.0b013e31815cb197. PMID 18091430.
C. L. Marchesoni, N. Roa u. a.: Misdiagnosis in Fabry disease. In: The Journal of pediatrics. Band 156, Nummer 5, Mai 2010, S. 828–831, doi:10.1016/j.jpeds.2010.02.012. PMID 20385321.
A. Mehta, R. Ricci u. a.: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. In: European journal of clinical investigation. Band 34, Nummer 3, März 2004, S. 236–242, doi:10.1111/j.1365-2362.2004.01309.x. PMID 15025684.
B. Hoffmann, H. Georg Koch u. a.: Deficient alpha-galactosidase A activity in plasma but no Fabry disease–a pitfall in diagnosis. In: Clinical chemistry and laboratory medicine. Band 43, Nummer 11, 2005, S. 1276–1277, doi:10.1515/CCLM.2005.219. PMID 16232095.
G. E. Linthorst, A. C. Vedder u. a.: Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. In: Clinica chimica acta. Band 353, Nummer 1–2, März 2005, S. 201–203, doi:10.1016/j.cccn.2004.10.019. PMID 15698608.
S. Roy, K. Gaudin u. a.: Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease. In: Journal of chromatography B. Band 805, Nummer 2, Juni 2004, S. 331–337, doi:10.1016/j.jchromb.2004.03.037. PMID 15135109.
C. Auray-Blais, D. Cyr u. a.: Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. In: Journal of inherited metabolic disease. Band 30, Nummer 1, Februar 2007, S. 106, doi:10.1007/s10545-006-0444-3. PMID 17171433.
C. Auray-Blais, D. Cyr u. a.: Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. In: Molecular Genetics and Metabolism. Band 93, Nummer 3, März 2008, S. 331–340, doi:10.1016/j.ymgme.2007.10.001. PMID 18023222.
D. Touboul, S. Roy u. a.: Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease. In: Analytical and bioanalytical chemistry. Band 382, Nummer 5, Juli 2005, S. 1209–1216, doi:10.1007/s00216-005-3239-8. PMID 15959771.
K. Mills, P. Morris u. a.: Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. In: Journal of inherited metabolic disease. Band 28, Nummer 1, 2005, S. 35–48, doi:10.1007/s10545-005-5263-4. PMID 15702404.
R. J. Desnick: Prenatal diagnosis of Fabry disease. In: Prenatal diagnosis. Band 27, Nummer 8, August 2007, S. 693–694, doi:10.1002/pd.1767. PMID 17533632. (Review).
T. F. Metz, T. P. Mechtler u. a.: Simplified newborn screening protocol for lysosomal storage disorders. In: Clinical chemistry. Band 57, Nummer 9, September 2011, S. 1286–1294, doi:10.1373/clinchem.2011.164640. PMID 21771947.
K. Nakamura, K. Hattori, F. Endo: Newborn screening for lysosomal storage disorders. In: American journal of medical genetics. Band 157, Nummer 1, Februar 2011, S. 63–71, doi:10.1002/ajmg.c.30291. PMID 21312327. (Review).
M. Beck: Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson-Fabry disease. In: Expert opinion on investigational drugs. Band 11, Nummer 6, Juni 2002, S. 851–858, doi:10.1517/13543784.11.6.851. PMID 12036428. (Review).
K. Lee, X. Jin u. a.: A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. In: Glycobiology. Band 13, Nummer 4, April 2003, S. 305–313, doi:10.1093/glycob/cwg034. PMID 12626384.
W. R. Wilcox, M. Banikazemi u. a.: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. In: American journal of human genetics. Band 75, Nummer 1, Juli 2004, S. 65–74, doi:10.1086/422366. PMID 15154115. PMC 1182009 (freier Volltext).
B. L. Thurberg, H. Rennke u. a.: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. In: Kidney International. Band 62, Nummer 6, Dezember 2002, S. 1933–1946, doi:10.1046/j.1523-1755.2002.00675.x. PMID 12427118.
J. Marshall, K. M. Ashe u. a.: Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. In: PloS one. Band 5, Nummer 11, 2010, S. e15033, doi:10.1371/journal.pone.0015033. PMID 21124789. PMC 2991350 (freier Volltext). (Open Access)
M. Beck: Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. In: Expert opinion on biological therapy. Band 9, Nummer 2, Februar 2009, S. 255–261, doi:10.1517/14712590802658428. PMID 19236256. (Review).
D. P. Germain, S. Waldek u. a.: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. In: JASN. Band 18, Nummer 5, Mai 2007, S. 1547–1557, doi:10.1681/ASN.2006080816. PMID 17409312.
Y. Tajima, I. Kawashima u. a.: Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. In: American journal of human genetics. Band 85, Nummer 5, November 2009, S. 569–580, doi:10.1016/j.ajhg.2009.09.016. PMID 19853240. PMC 2775840 (freier Volltext).
T. Ohashi, M. Sakuma u. a.: Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. In: Molecular Genetics and Metabolism. Band 92, Nummer 3, November 2007, S. 271–273, doi:10.1016/j.ymgme.2007.06.013. PMID 17689998.
T. Ohashi, S. Iizuka u. a.: Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. In: Molecular Genetics and Metabolism. Band 94, Nummer 3, Juli 2008, S. 313–318, doi:10.1016/j.ymgme.2008.03.008. PMID 18456533.
Maarten Arends, Marieke Biegstraaten u. a.: Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. In: Journal of Medical Genetics. Band 55, 2018, S. 351, doi:10.1136/jmedgenet-2017-104863.
C. A. Black: To march in or not to march in. In: Nature medicine. Band 17, Nummer 8, 2011, S. 921, doi:10.1038/nm.2440. PMID 21818082.
E. Dolgin: NIH faces marching orders on orphan drug shortage. In: Nature medicine. Band 17, Nummer 5, Mai 2011, S. 522, doi:10.1038/nm0511-522b. PMID 21546953.
B. Hoffmann, E. Mayatepek: Fabry disease-often seen, rarely diagnosed. In: Deutsches Ärzteblatt international. Band 106, Nummer 26, Juni 2009, S. 440–447, doi:10.3238/arztebl.2009.0440. PMID 19623315. PMC 270439 (freier Volltext). (Review).
Malte Lenders, Solvey Pollmann, Melina Terlinden, Eva Brand: Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. In: . 2022, Band 26, S. 323–330. doi:10.1016/j.omtm.2022.07.009.
Sam Kant, Mohamed G. Atta: Therapeutic advances in Fabry disease: The future awaits. In: . 2020, Band 131, S. 110779. doi:10.1016/j.biopha.2020.110779.
S. Ishii, H. H. Chang u. a.: Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. In: The Biochemical journal. Band 406, Nummer 2, September 2007, S. 285–295, doi:10.1042/BJ20070479. PMID 17555407. PMC 1948963 (freier Volltext).
G. Andreotti, M. R. Guarracino u. a.: Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 36, doi:10.1186/1750-1172-5-36. PMID 21138548. PMC 3016270 (freier Volltext). (Open Access)
R. Khanna, R. Soska u. a.: The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. In: Molecular therapy. Band 18, Nummer 1, Januar 2010, S. 23–33, doi:10.1038/mt.2009.220. PMID 19773742. PMC 2839206 (freier Volltext).
S. H. Shin, S. Kluepfel-Stahl u. a.: Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. In: Pharmacogenetics and genomics. Band 18, Nummer 9, September 2008, S. 773–780, doi:10.1097/FPC.0b013e32830500f4. PMID 18698230. PMC 2657085 (freier Volltext).
T. Watt, A. P. Burlina u. a.: Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. In: Genetics in medicine. Band 12, Nummer 11, November 2010, S. 703–712, doi:10.1097/GIM.0b013e3181f13a4a. PMID 20885332.
R. Baron, A. Binder, G. Wasner: Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. In: Lancet neurology. Band 9, Nummer 8, August 2010, S. 807–819, doi:10.1016/S1474-4422(10)70143-5. PMID 20650402. (Review).
G. Cruccu, C. Sommer u. a.: EFNS guidelines on neuropathic pain assessment: revised 2009. In: European journal of neurology. Band 17, Nummer 8, August 2010, S. 1010–1018, doi:10.1111/j.1468-1331.2010.02969.x. PMID 20298428. (Review).
H. Tahir, L. L. Jackson, D. G. Warnock: Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. In: JASN. Band 18, Nummer 9, September 2007, S. 2609–2617, doi:10.1681/ASN.2006121400. PMID 17656478.
A. Abe, S. Gregory u. a.: Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. In: The Journal of clinical investigation. Band 105, Nummer 11, Juni 2000, S. 1563–1571, doi:10.1172/JCI9711. PMID 10841515. PMC 300859 (freier Volltext).
T. Heare, N. J. Alp u. a.: Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. In: Journal of inherited metabolic disease. Band 30, Nummer 1, Februar 2007, S. 79–87, doi:10.1007/s10545-006-0473-y. PMID 17189993.
G. M. Pastores, N. L. Barnett, E. H. Kolodny: An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. In: Clinical therapeutics. Band 27, Nummer 8, August 2005, S. 1215–1227, doi:10.1016/j.clinthera.2005.08.004. PMID 16199246.
C. E. Hollak, D. Hughes u. a.: Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. In: Pharmacoepidemiology and drug safety. Band 18, Nummer 9, September 2009, S. 770–777, doi:10.1002/pds.1779. PMID 19507165.
T. Takenaka, G. J. Murray u. a.: Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. In: PNAS. Band 97, Nummer 13, Juni 2000, S. 7515–7520, doi:10.1073/pnas.120177997. PMID 10840053. PMC 16577 (freier Volltext).
T. Yokoi, H. Kobayashi u. a.: Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease. In: The journal of gene medicine. Band 13, Nummer 5, Mai 2011, S. 262–268, doi:10.1002/jgm.1566. PMID 21520359.
J. Park, G. J. Murray u. a.: Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. In: PNAS. Band 100, Nummer 6, März 2003, S. 3450–3454, doi:10.1073/pnas.0537900100. PMID 12624185. PMC 152313 (freier Volltext).
G. Qin, T. Takenaka u. a.: Preselective gene therapy for Fabry disease. In: PNAS. Band 98, Nummer 6, März 2001, S. 3428–3433, doi:10.1073/pnas.061020598. PMID 11248095. PMC 30670 (freier Volltext).
Y. A. Ioannou, K. M. Zeidner u. a.: Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. In: American journal of human genetics. Band 68, Nummer 1, Januar 2001, S. 14–25, doi:10.1086/316953. PMID 11115376. PMC 1234907 (freier Volltext).
A. Mehta, J. T. Clarke u. a.: Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. In: Journal of medical genetics. Band 46, Nummer 8, August 2009, S. 548–552, doi:10.1136/jmg.2008.065904. PMID 19473999.
K. Hashimoto, B. G. Gross, W. F. Lever: Angiokeratoma Corporis Diffusum (Fabry). Histochemical and Electron Microscopic Studies of the Skin. In: The Journal of investigative dermatology. Band 44, Februar 1965, S. 119–128, doi:10.1038/jid.1965.22PMID 14258908.
A. Gal: Molecular genetics of Fabry disease and Genotype-phenotype correlation. In: D. Elstein, G. Altarescu, M. Beck (Hrsg.): Fabry disease. Verlag Springer, 2010, ISBN 978-90-481-9032-4, S. 3–19. eingeschränkte Vorschau in der Google-Buchsuche
R. O. Brady: Bone and muscle involvement in Fabry disease. In: D. Elstein, G. Altarescu, M. Beck (Hrsg.): Fabry Disease. Verlag Springer, 2010, ISBN 978-90-481-9032-4, S. 293–298 eingeschränkte Vorschau in der Google-Buchsuche
A. M. Das: Angeborene Stoffwechselstörungen. In: A. Rieder, B. Lohff (Hrsg.): Gender Medizin. Verlag Springer, 2004, ISBN 3-211-00766-0, S. 67f.eingeschränkte Vorschau in der Google-Buchsuche
U. Fricke, U. Schwabe: Neue Arzneimittel 2007. In: U. Schwabe, D. Paffrath (Hrsg.): Arzneiverordnungs-Report 2008. Verlag Springer, 2008, S. 74. eingeschränkte Vorschau in der Google-Buchsuche
S. Biastoff, B. Dräger: Calystegines. In: G. A. Cordell (Hrsg.): The Alkaloids: Chemistry and Biology. S. 91. eingeschränkte Vorschau in der Google-Buchsuche
S. H. Kim, P. D. Robbins: Retroviral vectors for gene therapy. In: J. A. Barranger, M. A. Cabrera-Salazar (Hrsg.): Lysosomal storage disorders. Verlag Springer, 2007, ISBN 978-0-387-70908-6, S. 53–63. eingeschränkte Vorschau in der Google-Buchsuche
J. E. Scherberich: Hereditäre Nierenerkrankungen. In: G. Steinbeck, G. Paumgartner: Therapie innerer Krankheiten. Verlag Springer, 2005, ISBN 3-540-23750-X, S. 576. eingeschränkte Vorschau in der Google-Buchsuche
B. J. Poorthuis, R. A. Wevers u. a.: The frequency of lysosomal storage diseases in The Netherlands. In: Human genetics. Band 105, Nummer 1–2, 1999 Jul-Aug, S. 151–156. PMID 10480370.
M. Spada, S. Pagliardini u. a.: High incidence of later-onset fabry disease revealed by newborn screening. In: American journal of human genetics. Band 79, Nummer 1, Juli 2006, S. 31–40, doi:10.1086/504601. PMID 16773563. PMC 1474133 (freier Volltext).
W. L. Hwu, Y. H. Chien u. a.: Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). In: Human mutation. Band 30, Nummer 10, Oktober 2009, S. 1397–1405, doi:10.1002/humu.21074. PMID 19621417. PMC 2769558 (freier Volltext).
K. F. Gold, G. M. Pastores u. a.: Quality of life of patients with Fabry disease. In: Qual Life Res. Band 11, Nummer 4, Juni 2002, S. 317–327. PMID 12086117.
H. Y. Lin, K. W. Chong u. a.: High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. In: Circulation. Cardiovascular genetics. Band 2, Nummer 5, Oktober 2009, S. 450–456, doi:10.1161/CIRCGENETICS.109.862920. PMID 20031620.
P. Gaspar, J. Herrera u. a.: Frequency of Fabry disease in male and female haemodialysis patients in Spain. In: BMC medical genetics. Band 11, 2010, S. 19, doi:10.1186/1471-2350-11-19. PMID 20122163. PMC 2837018 (freier Volltext).
A. P. Burlina, K. B. Sims u. a.: Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. In: BMC neurology. Band 11, 2011, S. 61, doi:10.1186/1471-2377-11-61. PMID 21619592. PMC 3126707 (freier Volltext).
L. L. Pinto, T. A. Vieira u. a.: Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 14, doi:10.1186/1750-1172-5-14. PMID 20509947. PMC 2889886 (freier Volltext). (Review im Open Access)
D. P. Germain, K. Benistan, L. Angelova: X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. In: La Revue de médecine interne. Band 31, Suppl 2, Dezember 2010, S. S209–S213, doi:10.1016/S0248-8663(10)70013-8. PMID 21211665.
W. B. Dobyns, A. Filauro u. a.: Inheritance of most X-linked traits is not dominant or recessive, just X-linked. In: American journal of medical genetics. Part A. Band 129A, Nummer 2, August 2004, S. 136–143, doi:10.1002/ajmg.a.30123. PMID 15316978.
W. B. Dobyns: The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. In: Acta paediatrica. Band 95, Nummer 451, April 2006, S. 11–15, doi:10.1111/j.1651-2227.2006.tb02383.x. PMID 16720459.
M. Kobayashi, T. Ohashi u. a.: Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. In: Journal of inherited metabolic disease. [elektronische Veröffentlichung vor dem Druck] Januar 2008, doi:10.1007/s10545-007-0740-6. PMID 18202903.
I. Redonnet-Vernhet, J. K. Ploos van Amstel u. a.: Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. In: Journal of medical genetics. Band 33, Nummer 8, August 1996, S. 682–688. PMID 8863162. PMC 1050704 (freier Volltext).
E. M. Maier, S. Osterrieder u. a.: Disease manifestations and X inactivation in heterozygous females with Fabry disease. In: Acta paediatrica. Band 95, Nummer 451, April 2006, S. 30–38, doi:10.1111/j.1651-2227.2006.tb02386.x. PMID 16720462.
M. D. Sanchez-Niño, A. B. Sanz u. a.: Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. In: Nephrology, dialysis, transplantation. Band 26, Nummer 6, Juni 2011, S. 1797–1802, doi:10.1093/ndt/gfq306. PMID 20504837.
A. C. Vedder, G. E. Linthorst u. a.: Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. In: PloS one. Band 2, Nummer 7, 2007, S. e598, doi:10.1371/journal.pone.0000598. PMID 17622343. PMC 1913555 (freier Volltext). (Open Access)
K. D. MacDermot, A. Holmes, A. H. Miners: Natural history of Fabry disease in affected males and obligate carrier females. In: Journal of inherited metabolic disease. Band 24 Suppl 2, 2001, S. 13–14. PMID 11758673.
C. Whybra, C. Kampmann u. a.: Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. In: Journal of inherited metabolic disease. Band 24, Nummer 7, Dezember 2001, S. 715–724. PMID 11804208.
P. B. Deegan, A. F. Baehner u. a.: Natural history of Fabry disease in females in the Fabry Outcome Survey. In: Journal of medical genetics. Band 43, Nummer 4, April 2006, S. 347–352, doi:10.1136/jmg.2005.036327. PMID 16227523. PMC 2563231 (freier Volltext).
S. Gupta, M. Ries u. a.: The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. In: Medicine. Band 84, Nummer 5, September 2005, S. 261–268. PMID 16148726.
A. C. Vedder, G. E. Linthorst u. a.: The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. In: Journal of inherited metabolic disease. Band 30, Nummer 1, Februar 2007, S. 68–78, doi:10.1007/s10545-006-0484-8. PMID 17206462.
A. C. Vedder, A. Strijland u. a.: Manifestations of Fabry disease in placental tissue. In: Journal of inherited metabolic disease. Band 29, Nummer 1, Februar 2006, S. 106–111, doi:10.1007/s10545-006-0196-0. PMID 16601876.
E. Young, K. Mills u. a.: Is globotriaosylceramide a useful biomarker in Fabry disease? In: Acta paediatrica. Band 94, Nummer 447, März 2005, S. 51–54. PMID 15895713.
S. Bekri, O. Lidove u. a.: The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. In: Cardiovascular & hematological agents in medicinal chemistry. Band 4, Nummer 4, Oktober 2006, S. 289–297. PMID 17073606. (Review).
J. M. Aerts, J. E. Groener u. a.: Elevated globotriaosylsphingosine is a hallmark of Fabry disease. In: PNAS. Band 105, Nummer 8, Februar 2008, S. 2812–2817, doi:10.1073/pnas.0712309105. PMID 18287059. PMC 2268542 (freier Volltext).
A. H. Miners, A. Holmes u. a.: Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. In: Quality of life research. Band 11, Nummer 2, März 2002, S. 127–133. PMID 12018736.
D. A. Laney, D. J. Gruskin u. a.: Social-adaptive and psychological functioning of patients affected by Fabry disease. In: Journal of inherited metabolic disease. Januar 2010, doi:10.1007/s10545-009-9025-6. PMID 20087663.
J. Sadek, R. Shellhaas u. a.: Psychiatric findings in four female carriers of Fabry disease. In: Psychiatric genetics. Band 14, Nummer 4, Dezember 2004, S. 199–201. PMID 15564893.
A. L. Cole, P. J. Lee u. a.: Depression in adults with Fabry disease: a common and under-diagnosed problem. In: Journal of inherited metabolic disease. Band 30, Nummer 6, November 2007, S. 943–951, doi:10.1007/s10545-007-0708-6. PMID 17994284.
P. Segal, Y. Kohn u. a.: Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study. In: Journal of inherited metabolic disease. Band 33, Nummer 4, August 2010, S. 429–436, doi:10.1007/s10545-010-9133-3. PMID 20549363.
T. W. Crosbie, W. Packman, S. Packman: Psychological aspects of patients with Fabry disease. In: Journal of inherited metabolic disease. Band 32, Nummer 6, Dezember 2009, S. 745–753, doi:10.1007/s10545-009-1254-1. PMID 19924564.
W. J. Cable, E. H. Kolodny, R. D. Adams: Fabry disease: impaired autonomic function. In: Neurology. Band 32, Nummer 5, Mai 1982, S. 498–502. PMID 6803189.
M. Dütsch, H. Marthol u. a.: Small fiber dysfunction predominates in Fabry neuropathy. In: Journal of clinical neurophysiology. Band 19, Nummer 6, Dezember 2002, S. 575–586. PMID 12488789.
B. Hoffmann, M. Beck u. a.: Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. In: The Clinical journal of pain. Band 23, Nummer 6, Jul-Aug 2007, S. 535–542, doi:10.1097/AJP.0b013e318074c986. PMID 17575495.
R. J. Hopkin, J. Bissler u. a.: Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. In: Pediatric research. Band 64, Nummer 5, November 2008, S. 550–555, doi:10.1203/PDR.0b013e318183f132. PMID 18596579.
J. Charrow: A 14-year-old boy with pain in hands and feet. In: Pediatric annals. Band 38, Nummer 4, April 2009, S. 190, 192. PMID 19455947.
M. J. Hilz, B. Stemper, E. H. Kolodny: Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. In: Pain. Band 84, Nummer 2–3, Februar 2000, S. 361–365. PMID 10666542.
K. J. Sheth, S. L. Werlin u. a.: Gastrointestinal structure and function in Fabry’s disease. In: The American Journal of Gastroenterology. Band 76, Nummer 3, September 1981, S. 246–251. PMID 6274188.
B. Hoffmann, M. Schwarz u. a.: Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. In: Clinical gastroenterology and hepatology. Band 5, Nummer 12, Dezember 2007, S. 1447–1453, doi:10.1016/j.cgh.2007.08.012. PMID 17919989.
W. H. Kang, S. I. Chun, S. Lee: Generalized anhidrosis associated with Fabry’s disease. In: Journal of the American Academy of Dermatology. Band 17, Nummer 5 Pt 2, November 1987, S. 883–887. PMID 3119682.
C. H. Orteu, T. Jansen u. a.: Fabry disease and the skin: data from FOS, the Fabry outcome survey. In: The British journal of dermatology. Band 157, Nummer 2, August 2007, S. 331–337, doi:10.1111/j.1365-2133.2007.08002.x. PMID 17573884.
S. N. Gupta, M. Ries u. a.: Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study. In: BMC neurology. Band 8, 2008, S. 41, doi:10.1186/1471-2377-8-41. PMID 18990229. PMC 2585087 (freier Volltext). (Open Access)
E. D. Shelley, W. B. Shelley, T. W. Kurczynski: Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. In: Pediatric dermatology. Band 12, Nummer 3, September 1995, S. 215–219. PMID 7501549.
C. M. Eng, D. P. Germain u. a.: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. In: Genetics in medicine. Band 8, Nummer 9, September 2006, S. 539–548, doi:10.1097/01.gim.0000237866.70357.c6. PMID 16980809. (Review).
M. Möhrenschlager, M. Braun-Falco u. a.: Fabry disease: recognition and management of cutaneous manifestations. In: American journal of clinical dermatology. Band 4, Nummer 3, 2003, S. 189–196. PMID 12627994. (Review).
D. Wattanasirichaigoon, J. Svasti u. a.: Clinical and molecular characterization of an extended family with Fabry disease. In: Journal of the Medical Association of Thailand. Band 89, Nummer 9, September 2006, S. 1528–1535. PMID 17100396.
C. Orssaud, J. Dufier, D. Germain: Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. In: Ophthalmic genetics. Band 24, Nummer 3, September 2003, S. 129–139. PMID 12868031.
T. T. Nguyen, T. Gin u. a.: Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. In: Clinical & experimental ophthalmology. Band 33, Nummer 2, April 2005, S. 164–168, doi:10.1111/j.1442-9071.2005.00990.x. PMID 15807825.
A. Sodi, A. S. Ioannidis u. a.: Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. In: The British journal of ophthalmology. Band 91, Nummer 2, Februar 2007, S. 210–214, doi:10.1136/bjo.2006.100602. PMID 16973664. PMC 1857640 (freier Volltext).
K. Falke, A. Büttner u. a.: The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. In: Graefe’s archive for clinical and experimental ophthalmology. Band 247, Nummer 4, April 2009, S. 523–534, doi:10.1007/s00417-008-0962-9. PMID 18931853.
A. Sessa, M. Meroni u. a.: Renal pathological changes in Fabry disease. In: Journal of inherited metabolic disease. Band 24 Suppl 2, 2001, S. 66–70. PMID 11758681. (Review).
A. Sessa, M. Meroni u. a.: Evolution of renal pathology in Fabry disease. In: Acta paediatrica. Band 92, Nummer 443, Dezember 2003, S. 6–8. PMID 14989458.
A. B. Fogo, L. Bostad u. a.: Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). In: Nephrology, dialysis, transplantation. Band 25, Nummer 7, Juli 2010, S. 2168–2177, doi:10.1093/ndt/gfp528. PMID 19833663. PMC 2902894 (freier Volltext).
M. C. Gubler, G. Lenoir u. a.: Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. In: Kidney International. Band 13, Nummer 3, März 1978, S. 223–235. PMID 418264.
J. Alroy, S. Sabnis, J. B. Kopp: Renal pathology in Fabry disease. In: JASN. Band 13 Suppl 2, Juni 2002, S. S134–S138. PMID 12068025. (Review).
T. Thomaidis, M. Relle u. a.: Wirkung der Enzymersatztherapie (ERT) auf die Nierenfunktion von Patienten mit Morbus Fabry. In: Medizinische Klinik. Band 104, Nummer 9, September 2009, S. 699–703, doi:10.1007/s00063-009-1152-1. PMID 19779674. (Review).
M. H. Branton, R. Schiffmann u. a.: Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. In: Medicine. Band 81, Nummer 2, März 2002, S. 122–138. PMID 11889412.
R. Schiffmann, D. G. Warnock u. a.: Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. In: Nephrology, dialysis, transplantation. Band 24, Nummer 7, Juli 2009, S. 2102–2111, doi:10.1093/ndt/gfp031. PMID 19218538. PMC 2698092 (freier Volltext).
M. Senechal, D. P. Germain: Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. In: Clinical genetics. Band 63, Nummer 1, Januar 2003, S. 46–52. PMID 12519371.
J. S. Shah, D. A. Hughes u. a.: Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. In: The American journal of cardiology. Band 96, Nummer 6, September 2005, S. 842–846, doi:10.1016/j.amjcard.2005.05.033. PMID 16169374.
P. M. Elliott, H. Kindler u. a.: Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. In: Heart. Band 92, Nummer 3, März 2006, S. 357–360, doi:10.1136/hrt.2004.054015. PMID 16085718. PMC 1860797 (freier Volltext).
J. C. Moon, M. Sheppard u. a.: The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. In: J Cardiovasc Magn Reson. Band 8, Nummer 3, 2006, S. 479–482. PMID 16755835.
F. Weidemann, F. Breunig u. a.: The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. In: European heart journal. Band 26, Nummer 12, Juni 2005, S. 1221–1227, doi:10.1093/eurheartj/ehi143. PMID 15728649.
C. Kampmann, A. Linhart u. a.: Onset and progression of the Anderson-Fabry disease related cardiomyopathy. In: International journal of cardiology. Band 130, Nummer 3, November 2008, S. 367–373, doi:10.1016/j.ijcard.2008.03.007. PMID 18572264.
T. Takenaka, H. Teraguchi u. a.: Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. In: Journal of cardiology. Band 51, Nummer 1, Februar 2008, S. 50–59, doi:10.1016/j.jjcc.2007.12.001. PMID 18522775.
M. Pieroni, C. Chimenti u. a.: Early detection of Fabry cardiomyopathy by tissue Doppler imaging. In: Circulation. Band 107, Nummer 15, April 2003, S. 1978–1984, doi:10.1161/01.CIR.0000061952.27445.A0. PMID 12668521.
F. Weidemann, F. Breunig u. a.: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. In: Circulation. Band 108, Nummer 11, September 2003, S. 1299–1301, doi:10.1161/01.CIR.0000091253.71282.04. PMID 12952834.
M. Pieroni, C. Chimenti u. a.: Tissue Doppler imaging in Fabry disease. In: Current opinion in cardiology. Band 19, Nummer 5, September 2004, S. 452–457. PMID 15316452. (Review).
T. Palecek, G. Dostalova u. a.: Right ventricular involvement in Fabry disease. In: Journal of the American Society of Echocardiography. Band 21, Nummer 11, November 2008, S. 1265–1268, doi:10.1016/j.echo.2008.09.002. PMID 18835697.
M. Niemann, F. Breunig u. a.: The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. In: Heart. Band 96, Nummer 23, Dezember 2010, S. 1915–1919, doi:10.1136/hrt.2010.204586. PMID 20965976.
C. Kampmann, F. A. Baehner u. a.: The right ventricle in Fabry disease. In: Acta paediatrica. Band 94, Nummer 447, März 2005, S. 15–18. PMID 15895706.
A. Fellgiebel, M. J. Müller, L. Ginsberg: CNS manifestations of Fabry’s disease. In: Lancet neurology. Band 5, Nummer 9, September 2006, S. 791–795, doi:10.1016/S1474-4422(06)70548-8. PMID 16914407.
P. Mitsias, S. R. Levine: Cerebrovascular complications of Fabry’s disease. In: Annals of neurology. Band 40, Nummer 1, Juli 1996, S. 8–17, doi:10.1002/ana.410400105. PMID 8687196.
M. F. Mendez, T. M. Stanley u. a.: The vascular dementia of Fabry’s disease. In: Dementia and geriatric cognitive disorders. Band 8, Nummer 4, 1997 Jul-Aug, S. 252–257. PMID 9213072.
R. Okeda, M. Nisihara: An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. In: Neuropathology. Band 28, Nummer 5, Oktober 2008, S. 532–540, doi:10.1111/j.1440-1789.2008.00883.x. PMID 18410273.
A. Fellgiebel, I. Keller u. a.: Diagnostic utility of different MRI and MR angiography measures in Fabry disease. In: Neurology. Band 72, Nummer 1, Januar 2009, S. 63–68, doi:10.1212/01.wnl.0000338566.54190.8a. PMID 19122032.
T. DeGraba, S. Azhar u. a.: Profile of endothelial and leukocyte activation in Fabry patients. In: Annals of neurology. Band 47, Nummer 2, Februar 2000, S. 229–233. PMID 10665494.
C. R. Kaneski, D. F. Moore u. a.: Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. In: Neurology. Band 67, Nummer 11, Dezember 2006, S. 2045–2047, doi:10.1212/01.wnl.0000247278.88077.09. PMID 17159117. PMC 1950664 (freier Volltext).
A. Palla, S. Hegemann u. a.: Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. In: Journal of neurology. Band 254, Nummer 10, Oktober 2007, S. 1433–1442, doi:10.1007/s00415-007-0575-y. PMID 17934877.
Y. Sakurai, H. Kojima u. a.: The hearing status in 12 female and 15 male Japanese Fabry patients. In: Auris, nasus, larynx. Band 36, Nummer 6, Dezember 2009, S. 627–632, doi:10.1016/j.anl.2009.01.001. PMID 19261412.
D. P. Germain, P. Avan u. a.: Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. In: BMC medical genetics. Band 3, Oktober 2002, S. 10. PMID 12377100. PMC 134464 (freier Volltext).
G. Conti, B. Sergi: Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. In: Acta paediatrica. Band 92, Nummer 443, Dezember 2003, S. 33–37. PMID 14989464.
D. M. Rosenberg, V. J. Ferrans u. a.: Chronic airflow obstruction in Fabry’s disease. In: The American journal of medicine. Band 68, Nummer 6, Juni 1980, S. 898–905. PMID 6247911.
L. K. Brown, A. Miller u. a.: Pulmonary involvement in Fabry disease. In: American journal of respiratory and critical care medicine. Band 155, Nummer 3, März 1997, S. 1004–1010. PMID 9116979.
S. Magage, J. C. Lubanda u. a.: Atteinte respiratoire de la maladie de Fabry. In: Médecine sciences. Band 21, Nummer 11 Suppl, Dezember 2005, S. 37–39, doi:10.1051/medsci/20052111s37. PMID 16324666.
S. Magage, J. C. Lubanda u. a.: Natural history of the respiratory involvement in Anderson-Fabry disease. In: Journal of inherited metabolic disease. Band 30, Nummer 5, Oktober 2007, S. 790–799, doi:10.1007/s10545-007-0616-9. PMID 17619837.
D. P. Germain, K. Benistan u. a.: Atteinte osseuse de la maladie de Fabry. In: Médecine sciences. Band 21, Nummer 11 Suppl, Dezember 2005, S. 43–44, doi:10.1051/medsci/20052111s43. PMID 16324668.
D. P. Germain, K. Benistan u. a.: Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. In: Clinical genetics. Band 68, Nummer 1, Juli 2005, S. 93–95, doi:10.1111/j.1399-0004.2005.00457.x. PMID 15952993.
H. Mersebach, J. O. Johansson u. a.: Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. In: Genetics in medicine. Band 9, Nummer 12, Dezember 2007, S. 812–818, doi:10.1097/GIM.0b013e31815cb197. PMID 18091430.
C. L. Marchesoni, N. Roa u. a.: Misdiagnosis in Fabry disease. In: The Journal of pediatrics. Band 156, Nummer 5, Mai 2010, S. 828–831, doi:10.1016/j.jpeds.2010.02.012. PMID 20385321.
A. Mehta, R. Ricci u. a.: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. In: European journal of clinical investigation. Band 34, Nummer 3, März 2004, S. 236–242, doi:10.1111/j.1365-2362.2004.01309.x. PMID 15025684.
K. D. MacDermot, A. Holmes, A. H. Miners: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. In: Journal of medical genetics. Band 38, Nummer 11, November 2001, S. 750–760. PMID 11694547. PMC 173476 (freier Volltext).
J. S. Mayes, J. B. Scheerer u. a.: Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. In: Clinica chimica acta. Band 112, Nummer 2, Mai 1981, S. 247–251. PMID 6263521.
B. Hoffmann, H. Georg Koch u. a.: Deficient alpha-galactosidase A activity in plasma but no Fabry disease–a pitfall in diagnosis. In: Clinical chemistry and laboratory medicine. Band 43, Nummer 11, 2005, S. 1276–1277, doi:10.1515/CCLM.2005.219. PMID 16232095.
G. E. Linthorst, A. C. Vedder u. a.: Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. In: Clinica chimica acta. Band 353, Nummer 1–2, März 2005, S. 201–203, doi:10.1016/j.cccn.2004.10.019. PMID 15698608.
S. Roy, K. Gaudin u. a.: Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease. In: Journal of chromatography B. Band 805, Nummer 2, Juni 2004, S. 331–337, doi:10.1016/j.jchromb.2004.03.037. PMID 15135109.
C. Auray-Blais, D. Cyr u. a.: Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. In: Journal of inherited metabolic disease. Band 30, Nummer 1, Februar 2007, S. 106, doi:10.1007/s10545-006-0444-3. PMID 17171433.
C. Auray-Blais, D. Cyr u. a.: Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. In: Molecular Genetics and Metabolism. Band 93, Nummer 3, März 2008, S. 331–340, doi:10.1016/j.ymgme.2007.10.001. PMID 18023222.
D. Touboul, S. Roy u. a.: Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease. In: Analytical and bioanalytical chemistry. Band 382, Nummer 5, Juli 2005, S. 1209–1216, doi:10.1007/s00216-005-3239-8. PMID 15959771.
K. Mills, P. Morris u. a.: Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. In: Journal of inherited metabolic disease. Band 28, Nummer 1, 2005, S. 35–48, doi:10.1007/s10545-005-5263-4. PMID 15702404.
R. J. Desnick: Prenatal diagnosis of Fabry disease. In: Prenatal diagnosis. Band 27, Nummer 8, August 2007, S. 693–694, doi:10.1002/pd.1767. PMID 17533632. (Review).
T. F. Metz, T. P. Mechtler u. a.: Simplified newborn screening protocol for lysosomal storage disorders. In: Clinical chemistry. Band 57, Nummer 9, September 2011, S. 1286–1294, doi:10.1373/clinchem.2011.164640. PMID 21771947.
K. Nakamura, K. Hattori, F. Endo: Newborn screening for lysosomal storage disorders. In: American journal of medical genetics. Band 157, Nummer 1, Februar 2011, S. 63–71, doi:10.1002/ajmg.c.30291. PMID 21312327. (Review).
M. Beck: Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson-Fabry disease. In: Expert opinion on investigational drugs. Band 11, Nummer 6, Juni 2002, S. 851–858, doi:10.1517/13543784.11.6.851. PMID 12036428. (Review).
K. Lee, X. Jin u. a.: A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. In: Glycobiology. Band 13, Nummer 4, April 2003, S. 305–313, doi:10.1093/glycob/cwg034. PMID 12626384.
W. R. Wilcox, M. Banikazemi u. a.: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. In: American journal of human genetics. Band 75, Nummer 1, Juli 2004, S. 65–74, doi:10.1086/422366. PMID 15154115. PMC 1182009 (freier Volltext).
B. L. Thurberg, H. Rennke u. a.: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. In: Kidney International. Band 62, Nummer 6, Dezember 2002, S. 1933–1946, doi:10.1046/j.1523-1755.2002.00675.x. PMID 12427118.
J. Marshall, K. M. Ashe u. a.: Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. In: PloS one. Band 5, Nummer 11, 2010, S. e15033, doi:10.1371/journal.pone.0015033. PMID 21124789. PMC 2991350 (freier Volltext). (Open Access)
M. Beck: Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. In: Expert opinion on biological therapy. Band 9, Nummer 2, Februar 2009, S. 255–261, doi:10.1517/14712590802658428. PMID 19236256. (Review).
G. M. Keating, D. Simpson: Spotlight on agalsidase beta in Fabry disease. In: BioDrugs. Band 21, Nummer 4, 2007, S. 269–271. PMID 17628124. (Review).
D. P. Germain, S. Waldek u. a.: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. In: JASN. Band 18, Nummer 5, Mai 2007, S. 1547–1557, doi:10.1681/ASN.2006080816. PMID 17409312.
Y. Tajima, I. Kawashima u. a.: Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. In: American journal of human genetics. Band 85, Nummer 5, November 2009, S. 569–580, doi:10.1016/j.ajhg.2009.09.016. PMID 19853240. PMC 2775840 (freier Volltext).
T. Ohashi, M. Sakuma u. a.: Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. In: Molecular Genetics and Metabolism. Band 92, Nummer 3, November 2007, S. 271–273, doi:10.1016/j.ymgme.2007.06.013. PMID 17689998.
T. Ohashi, S. Iizuka u. a.: Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. In: Molecular Genetics and Metabolism. Band 94, Nummer 3, Juli 2008, S. 313–318, doi:10.1016/j.ymgme.2008.03.008. PMID 18456533.
C. A. Black: To march in or not to march in. In: Nature medicine. Band 17, Nummer 8, 2011, S. 921, doi:10.1038/nm.2440. PMID 21818082.
E. Dolgin: NIH faces marching orders on orphan drug shortage. In: Nature medicine. Band 17, Nummer 5, Mai 2011, S. 522, doi:10.1038/nm0511-522b. PMID 21546953.
B. Hoffmann, E. Mayatepek: Fabry disease-often seen, rarely diagnosed. In: Deutsches Ärzteblatt international. Band 106, Nummer 26, Juni 2009, S. 440–447, doi:10.3238/arztebl.2009.0440. PMID 19623315. PMC 270439 (freier Volltext). (Review).
S. Ishii, H. H. Chang u. a.: Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. In: The Biochemical journal. Band 406, Nummer 2, September 2007, S. 285–295, doi:10.1042/BJ20070479. PMID 17555407. PMC 1948963 (freier Volltext).
N. Asano, S. Ishii u. a.: In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. In: European Journal of Biochemistry. Band 267, Nummer 13, Juli 2000, S. 4179–4186. PMID 10866822.
G. Andreotti, M. R. Guarracino u. a.: Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 36, doi:10.1186/1750-1172-5-36. PMID 21138548. PMC 3016270 (freier Volltext). (Open Access)
R. Khanna, R. Soska u. a.: The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. In: Molecular therapy. Band 18, Nummer 1, Januar 2010, S. 23–33, doi:10.1038/mt.2009.220. PMID 19773742. PMC 2839206 (freier Volltext).
S. H. Shin, S. Kluepfel-Stahl u. a.: Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. In: Pharmacogenetics and genomics. Band 18, Nummer 9, September 2008, S. 773–780, doi:10.1097/FPC.0b013e32830500f4. PMID 18698230. PMC 2657085 (freier Volltext).
T. Watt, A. P. Burlina u. a.: Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. In: Genetics in medicine. Band 12, Nummer 11, November 2010, S. 703–712, doi:10.1097/GIM.0b013e3181f13a4a. PMID 20885332.
M. R. Filling-Katz, H. F. Merrick u. a.: Carbamazepine in Fabry’s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. In: Neurology. Band 39, Nummer 4, April 1989, S. 598–600. PMID 2494569.
R. Baron, A. Binder, G. Wasner: Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. In: Lancet neurology. Band 9, Nummer 8, August 2010, S. 807–819, doi:10.1016/S1474-4422(10)70143-5. PMID 20650402. (Review).
G. Cruccu, C. Sommer u. a.: EFNS guidelines on neuropathic pain assessment: revised 2009. In: European journal of neurology. Band 17, Nummer 8, August 2010, S. 1010–1018, doi:10.1111/j.1468-1331.2010.02969.x. PMID 20298428. (Review).
C. E. Argoff, N. W. Barton u. a.: Gastrointestinal symptoms and delayed gastric emptying in Fabry’s disease: response to metoclopramide. In: Nuclear medicine communications. Band 19, Nummer 9, September 1998, S. 887–891. PMID 10581595.
H. Tahir, L. L. Jackson, D. G. Warnock: Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. In: JASN. Band 18, Nummer 9, September 2007, S. 2609–2617, doi:10.1681/ASN.2006121400. PMID 17656478.
A. Abe, S. Gregory u. a.: Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. In: The Journal of clinical investigation. Band 105, Nummer 11, Juni 2000, S. 1563–1571, doi:10.1172/JCI9711. PMID 10841515. PMC 300859 (freier Volltext).
T. Heare, N. J. Alp u. a.: Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. In: Journal of inherited metabolic disease. Band 30, Nummer 1, Februar 2007, S. 79–87, doi:10.1007/s10545-006-0473-y. PMID 17189993.
G. M. Pastores, N. L. Barnett, E. H. Kolodny: An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. In: Clinical therapeutics. Band 27, Nummer 8, August 2005, S. 1215–1227, doi:10.1016/j.clinthera.2005.08.004. PMID 16199246.
C. E. Hollak, D. Hughes u. a.: Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. In: Pharmacoepidemiology and drug safety. Band 18, Nummer 9, September 2009, S. 770–777, doi:10.1002/pds.1779. PMID 19507165.
T. Ohshima, R. Schiffmann u. a.: Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. In: PNAS. Band 96, Nummer 11, Mai 1999, S. 6423–6427. PMID 10339603. PMC 26897 (freier Volltext).
T. Takenaka, G. J. Murray u. a.: Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. In: PNAS. Band 97, Nummer 13, Juni 2000, S. 7515–7520, doi:10.1073/pnas.120177997. PMID 10840053. PMC 16577 (freier Volltext).
T. Yokoi, H. Kobayashi u. a.: Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease. In: The journal of gene medicine. Band 13, Nummer 5, Mai 2011, S. 262–268, doi:10.1002/jgm.1566. PMID 21520359.
J. Park, G. J. Murray u. a.: Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. In: PNAS. Band 100, Nummer 6, März 2003, S. 3450–3454, doi:10.1073/pnas.0537900100. PMID 12624185. PMC 152313 (freier Volltext).
G. Qin, T. Takenaka u. a.: Preselective gene therapy for Fabry disease. In: PNAS. Band 98, Nummer 6, März 2001, S. 3428–3433, doi:10.1073/pnas.061020598. PMID 11248095. PMC 30670 (freier Volltext).
Y. A. Ioannou, K. M. Zeidner u. a.: Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. In: American journal of human genetics. Band 68, Nummer 1, Januar 2001, S. 14–25, doi:10.1086/316953. PMID 11115376. PMC 1234907 (freier Volltext).
M. E. Haskins, U. Giger, D. F. Patterson: Animal models of lysosomal storage diseases: their development and clinical relevance. In: A. Mehta, M. Beck, G. Sunder-Plassmann (Hrsg.): Fabry Disease: Perspectives from 5 Years of FOS. Kapitel 6, Oxford PharmaGenesis, 2006, ISBN 1-903539-03-X. PMID 21290677
K. D. MacDermot, A. Holmes, A. H. Miners: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. In: Journal of medical genetics. Band 38, Nummer 11, November 2001, S. 769–775. PMID 11732485. PMC 1734754 (freier Volltext).
A. Mehta, J. T. Clarke u. a.: Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. In: Journal of medical genetics. Band 46, Nummer 8, August 2009, S. 548–552, doi:10.1136/jmg.2008.065904. PMID 19473999.
H. Fabry: An historical overview of Fabry disease. In: Journal of inherited metabolic disease. Band 24, Suppl 2, 2001, S. 3–7. PMID 11758677.
A. W. Pompen, M. Ruiter, H. J. Wyers: Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. In: Acta medica Scandinavica. Band 128, Nummer 3, Juni 1947, S. 234–255. PMID 18897399.
H. Hornbostel, K. Scriba: Zur Diagnostik des Angiokeratoma Fabry mit kardiovasorenalem Symptomenkomplex als Phosphatidspeicherkrankheit durch Probeexcision der Haut. In: Klinische Wochenschrift. Band 31, Nummer 3–4, Januar 1953, S. 68–69. PMID 13062573.
J. R. Colley, D. L. Miller u. a.: The renal lesion in angiokeratoma corporis diffusum. In: British medical journal. Band 1, Nummer 5082, Mai 1958, S. 1266–1268. PMID 13536474. PMC 2028866 (freier Volltext).
J. M. Opitz, F. C. Stiles u. a.: The Genetics of Angiokeratoma Corporis Diffusum (Fabry’s Disease) and Its Linkage Relations with the Xg Locus. In: American journal of human genetics. Band 17, Nummer 4, Juli 1965, S. 325–342. PMID 17948499. PMC 1932618 (freier Volltext).
K. Hashimoto, B. G. Gross, W. F. Lever: Angiokeratoma Corporis Diffusum (Fabry). Histochemical and Electron Microscopic Studies of the Skin. In: The Journal of investigative dermatology. Band 44, Februar 1965, S. 119–128, doi:10.1038/jid.1965.22PMID 14258908.
J. A. Kint: Fabry’s disease: alpha-galactosidase deficiency. In: Science. Band 167, Nummer 922, Februar 1970, S. 1268–1269. PMID 5411915.
J. W. Kusiak, J. M. Quirk, R. O. Brady: Purification and properties of the two major isozymes of alpha-galactosidase from human placenta. In: The Journal of biological chemistry. Band 253, Nummer 1, Januar 1978, S. 184–190. PMID 201618.
R. J. Desnick, K. Y. Allen u. a.: Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. In: The Journal of laboratory and clinical medicine. Band 81, Nummer 2, Februar 1973, S. 157–171. PMID 4683418.
R. J. Desnick, K. J. Dean u. a.: Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. In: PNAS. Band 76, Nummer 10, Oktober 1979, S. 5326–5330. PMID 228284. PMC 413135 (freier Volltext).
C. A. Mapes, R. L. Anderson u. a.: Enzyme replacement in Fabry’s disease, an inborn error of metabolism. In: Science. Band 169, Nummer 949, September 1970, S. 987–989. PMID 4914726.
T. Ohshima, G. J. Murray u. a.: alpha-Galactosidase A deficient mice: a model of Fabry disease. In: PNAS. Band 94, Nummer 6, März 1997, S. 2540–2544. PMID 9122231. PMC 20124 (freier Volltext).
D. F. Bishop, D. H. Calhoun u. a.: Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. In: PNAS. Band 83, Nummer 13, Juli 1986, S. 4859–4863. PMID 3014515. PMC 323842 (freier Volltext).
R. Kornreich, R. J. Desnick, D. F. Bishop: Nucleotide sequence of the human alpha-galactosidase A gene. In: Nucleic Acids Research. Band 17, Nummer 8, April 1989, S. 3301–3302. PMID 2542896. PMC 317741 (freier Volltext).
D. F. Bishop, R. Kornreich, R. J. Desnick: Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. In: PNAS. Band 85, Nummer 11, Juni 1988, S. 3903–3907. PMID 2836863. PMC 280328 (freier Volltext).
R. Schiffmann, G. J. Murray u. a.: Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. In: PNAS. Band 97, Nummer 1, Januar 2000, S. 365–370. PMID 10618424. PMC 26669 (freier Volltext).
